Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Platelet-rich plasma (PRP) is an autologous biologic therapy consisting of a concentrated suspension of platelets derived from the patient's own blood. This preparation contains a high concentration of alpha-granules which, upon activation, release various growth factors including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF). These factors promote angiogenesis, mesenchymal stem cell recruitment, and extracellular matrix synthesis. In the clinical study led by Dr. Hamdy Singab, PRP is applied topically to the sternal edges during median sternotomy closure in open-heart surgery patients to accelerate bone healing and reduce the incidence of sternal dehiscence, particularly in high-risk populations such as those with diabetes or high BMI.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on platelet-rich plasma (5611e7).